FIGURE 1



Asc I (4517)
Bgl II (2)
CMV Prom
pUC origin
Hin d III (763)
IPpoI (858)
Chimeric Intron
T7 Promoter
pVVS431 (pKNexp)
4522 bp
MCS
Nhe I (1092)
Not I (1138)
HSV TK polyA
T3 Promoter
SV40 late polyA
Hpa I (1304)
Swa I (1416)
SV40 origin
Km/Neo
f1 origin
Bact Prom
SV40early Prom

FIGURE 2

FIGURE 2A: pVVS452 (pRSV-H90L)




Figure 2b: pVVS450 (pRSV-H90H)




FIGURE 3

Figure 3A: pVVS455 (pRSV-LH-H90)





Figure 3B: pVVS460 (pRSV-HL-H90)






FIGURE 4

FIGURE 5



A
IgG1 (ug/ml)
pEF1/HTLV (pVVS490)
IgG1 (ug/ml)
pRSV (pVVS455)
B
(IgG1 (ug/ml)
pEF1/HTLV
(pVVS490)
(IgG1 (ug/ml)
pRSV(pVVS455)
C
IgG1 (ug/ml)
pEF1/HTLV (pVVS490)
(IgG1 (ug/ml)
pRSV (pVVS455)
D
IgG1 (ug /mL)
75cm² flask
175cm² flask
Days in culture

FIGURE 6A




FIGURE 6B




FIGURE 6

FIGURE 7A




FIGURE 7B




FIGURE 7




WITHOUT FUCOSE: 48%
1906-(GlcNAc)3 + (Man)3(GlcNAc)2: 7%
1822-(Gal)1(GlcNAc)1 + (Man)3(GlcNAc)2: 1.5%
1865-(Gal)1(GlcNAc)2 + (Man)3(GlcNAc)2: 2.5%
2111-(Gal)(GlcNAc)3 + (Man)3(GlcNAc)2: 3%
2070-(Gal)2(GlcNAc)2 + (Man)3(GlcNAc)2: 1.5%
2315-(Gal)2(GlcNAc)3 + (Man)3(GlcNAc)2: 1.5%
1374-(Man)3(GlcNAc)2: 26%
1784-(Man)6(GlcNAc)2: 6%
Glc NAc
Mannose
Galactose
Fucose α1, 6
NeuAc α 2, 6
WITH FUCOSE: 52%
G0F: 1837-(GlcNAc)2(Fuc)1 + (Man)3(GlcNAc)2: 18%
G1F: 2040-(Gal)1(GlcNAc)2(Fuc)1 + (Man)3(GlcNAc)2: 24%
2213-(Gal)1(GlcNAc)2(Fuc)2 + (Man)3(GlcNAc)2: 2.5%
G2F: 2244-(Gal)2(GlcNAc)2(Fuc)1 + (Man)3(GlcNAc)2: 5%
2285-(Gal)1(GlcNAc)3(Fuc)1 + (Man)3(GlcNAc)2: 1%
1793-(Gal)1(GlcNAc)1(Fuc)1 + (Man)3(GlcNAc)2: 1.5%

FIGURE 8



Median results iof triplicate using 10µg proteins

FIGURE 9




% of Chromium Release (Donor 2)
Tumor
Tumor + Anti-Tumor IgG1 (10µg; mouse)
Tumor + Anti-Tumor (25µg; CHO)
Tumor + Anti-Tumor IgG1 (25µg; EB14)
80,0
70,0
60,0
50,0
40,0
30,0
20,0
10,0
0,0
NK Freshly Thawed
NK + 5U IL2
NK + 100U IL2
% of Chromium Release (Donor 1)
Tumor
Tumor + Anti-Tumor IgG1 (10µg; mouse)
Tumor + Anti-Tumor IgG1 (25µg; CHO)
Tumor + Anti-Tumor IgG1 25µg;(EB14)
50
45
40
35
30
25
20
15
10
5
0
NK Freshly Thawed
NK + 5U IL2
NK + 100U IL2


FIGURE 10

FIGURE 11

A


pVVS437 : pKN-puro
CMV prom
polyA
polyA
Puro
SV40 prom
SV40 prom
bact prom
Km/Neo
polyA
pUC Ori
intron
pVVS438 : pNR13-puro
RSV prom
cNR13
polyA
polyA
Puro
SV40 prom
SV40 prom
bact prom
Km/Neo
polyA
pUC Ori
intron

B


-
ADNg
NR13 (pVVS438)
-
pool EB45 + pVVS437
pool EB45 + NR13
clones EB45 pVVS437
1
2
3
clones EB45 pVVS438 (RSV-NR13)
B2
B3
B4
C1
RT GAPDH
RT NR13
Temoins non RT
RT sur ARNtotaux

C




FIGURE 11




FIGURE 12

FIGURE 13A




FIGURE 13B




FIGURE 13




FIGURE 14

FIGURE 15A




FIGURE 15B




FIGURE 15



Purified NK Cells
% Cr release
- ■ - CHO
- O - EB14
- ■ - Duck EBx
IgG1 (0.8 to 50µg/ml)
% Cr release
CHO - IL2 100U
EB14 - IL2 100U
Duck EBx - IL2 100U
IgG1 (0.8 to 50µg/ml)

FIGURE 16

FIGURE 17A




FIGURE 17B

